About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
R & D - Highlights
  > R & D
  Overview
  Principal Domains
  Skill Base
  Publications
  Highlights
  Discovery Pipeline
  Intellectual Property
  Active Discovery Programs
 
  Home
 
     
 

Highlights

2016

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting

Biocon's Insulin Glargine Receives Regulatory Approval in Japan

Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA

Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY 17

Biocon Announces Data from Key Studies for Insulin Tregopil


2015

Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India

Biocon Inaugurates World Class Devices Facility & Introduces Basalog One™ Forges Ahead on 'Make in India for the World' Mission

Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed


2014

Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb® to Treat SIRS and Cardiac Surgery Patients

Bristol-Myers Squibb and Syngene International Extend Research Collaboration

Shri Ghulam Nabi Azad Inaugurates Baxter Global Research Center at Syngene

Biocon Collaborates with Advaxis for 'ADXS-HPV'A Novel Cancer Immunotherapy

2013

Biocon Launched ALZUMAb- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India

Biocon Enhances Partnership with Mylan through Strategic Collaboration for Insulin Products

Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis


2012

Biocon enters into an agreement with Bristol-Myers Squibb for its Insulin Tregopil drug

Biocon announced Positive Results from its Global Phase 3 study with Recombinant Human Insulin

Biocon announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine

Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoiasis


2010

Biocon announces preliminary data on its novel Insulin Tregopil drug candidate

Biocon initiates Phase 3 clinical trials in Psoriasis


2009

Biocon completes Phase 2 clinical trials in Psoriasis and Rheumatoid Arthritis.

Biocon initiates Insulin Tregopil Phase 3 study in Type 2 diabetes.

Biocon completed Phase 3 studies using Insulin Glargine and have got regulatory approval for Marketing


2
008

Biocon presents data on Insulin Tregopil at the European Association for Study of Diabetes, Rome

Biocon completed Phase 2 studies using Insulin Tregopil in T2DM subjects

Biocon initiates Phase 2 studies using T1h in Psoriasis patients

Biocon completes Phase 1 clinical trial using Insulin Tregopil in NHV in Europe

Biocon initiates collaboration with Iatrica Inc. on development on novel NucleoMabs for Oncology


2007

Biocon initiates Phase 1 Clinical Trials in Europe after getting approvals from the MPA (Sweden)

Biocon initiates clinical trial of T1h in Rheumatoid Arthritis

Additional clinical trials for use of BIOMAb EGFR® in the treatment of glioma and non-small cell lung carcinoma initiated

Biocon unveils five renal therapy drugs

Biocon gets regulatory approval for GCSF

Biocon gets regulatory approval for Streptokinase

Biocon signs pact with Deakin University to jointly develop a mammalian cell bio-processing facility


2006

Biocon files PCT for novel process of manufacturing of Oral Insulin

Biocon completes phase-IV trials of INSUGEN®

Biocon launches BIOMAb-EGFR® a therapeutic monoclonal antibody-based drug for treating solid tumors of epithelial origin


2005

Biocon acquires the intellectual property of Nobex Corporation. With it, Biocon's total IP estate increases by nearly 300 patents and patent applications focused on oral peptide therapeutics in the metabolic and cardiovascular segment

Biocon and Karolinska Institute sign a MoU to collaborate in research and research education initiatives


2004

Biocon and Vaccinex partner to discover and develop therapeutic antibodies

Biocon launches INSUGEN®, the world's first recombinant human (r-DNA) insulin using a unique Pichia expression system


2003

Biocon files its 100th patent application


2002

Biocon ranks 3rd among Indian companies for filing PCT applications

Biocon files PCT application for patent on 'Methods of producing esters of Mycophenolate'

US patent office grants 3 patents on the process for the manufacture of Simvastatin

FDA approves a solid state process for the manufacture of Lovastatin


2001

US patent office grants a patent on PlaFractor, Biocon's revolutionary bioreactor

 
     
Highlights
 
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved